5. Editorial Policies

Publishing rights are entitled to the author(s) until publication, which is automatically transferred to the Editorial Board and the Publisher unless specified otherwise by the author at the time of submission. When submitting the manuscript, the author should declare in a signed cover letter that this is the first publication, which is offered to Promenade Publishing House for publication in Cardiologia Hungarica, and it is known and accepted by all authors and there is no conflict of interest. Thereafter the Editorial Board and the Publisher are entitled to have global copyright. The Publisher does not reject the request for republication. Further republication is not generally accepted.

A different practice can be applied, when:

the material was published in the form of an abstract or a poster in a preliminary report at a scientific meeting, or a part of it has been published in the form of proceedings of a scientific event.

the republication will be published in a different language (e.g.: in the mother tongue), in which case a written permission from the publisher should be provided. In the cover letter, all authors must declare that they have complied with the international ethical standards. Patients have the fundamental right to preserve their anonymity, which can only be ignored if the patient received detailed information and their written agreement is attached by the author. Information which can be used to identify the person (text, graphics) can only be published with the consent of the patient. In the case of clinical trials which require permission from the Ethics Committee, please attach a copy of the permit. All authors must declare whether they have a financial conflict of interest with the manufacturer / distributor of the diagnostic or therapeutic procedure / active substance, or with the sponsors of the procedures described in the study. The Editorial Board reserves the right to present this fact in the study in the case of a major financial relationship.

5.1 Policy on Conflict of Interest

The authors are requested to provide details of conflicts of interest, if any, or declare no conflict of interest on the downloadable form below. This is a requirement on the submission of the manuscript.

Download Conflict of Interest Statement

5.2 Policies on Human and Animal Rights

When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national). If doubt exists whether the research was conducted in accordance with the ethical standards, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. When reporting experiments on animals, authors are requested to indicate whether the institutional and national guide for the care and use of laboratory animals was followed.

All studies conducted on animals should have ethics committe approval, which should be included in the manuscript.

5.3 Ethics and Informed Consent

All research involving human subjects should be approved by the appropriate IRB/IEC. Written informed consent should be given by participants and the conduct of the study should adhere to the principles of Good Clinical Practice, local and national laws and regulations and ethical principles outlined by the Declaration of Helsinki.

An ethics statement should be included in the manuscript if ethical review was required for the study, stating that the study was reviewed and approved by the appropriate ethics committee. Please state the name of the ethics committee and the approval number as well.

The authors of the articles respect the patients’ right to privacy. Any identifying information – such as names, initials etc. – or photographs should not be published in written material unless the information is essential for scientific purposes and the patient (parent/guardian) gives written informed consent for publication. However, identifying details should be omitted if they are not essential.

Informed consent for this purpose requires that the manuscript to be published is shown to the identifiable patient.

If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

For manuscripts containing patient identifiable information, a Statement of Informed Consent should be attached to the manuscript. This applies to all original papers, including original research, editorials, state of the art papers, brief reports, case reports, images in medicine, and also for comments on clinical trials.

Download Statement of Informed Consent

5.4 Data Availability and Data Sharing Policies

The report of clinical trials must contain a data sharing statement. Clinical trials that began enrolling participants on or after 1 January 2019 must include a data sharing plan in the submission. If the data sharing plan changes, this should be reflected in the statement submitted and published with the manuscript.

The following information must be contained in the data sharing statement: whether individual de-identified participant data will be shared; what data will be shared; whether additional documents will be available (study protocol, statistical analysis plan, etc.); when and for how long the data will become available; with whom will the data be shared for and the means of sharing; analytic methods used. Authors of secondary analyses of the shared data must acknowledge that their use was in accordance with the terms agreed to upon their receipt.

In the data availability statement, authors should clarify how and what datasets can be made available.

5.5 Funding

Information on the funding of the work must be included in the manuscript on submission. This includes grant numbers as well, if applicable.

5.6 Open access

Articles in Cardiologia Hungarica are published under the CC-BY 4.0 International licence.